WO2012036344A1

WO2012036344A1 - Appetite suppressant food composition comprising a specific compound as an active ingredient

Info

Publication number: WO2012036344A1
Application number: PCT/KR2010/008111
Authority: WO
Inventors: 김인호; 한대석; 이창호; 조승목
Original assignee: 한국식품연구원
Priority date: 2010-09-17
Filing date: 2010-11-16
Publication date: 2012-03-22

Abstract

The present invention relates to an appetite suppressant food composition comprising a specific compound as an active ingredient. More particularly, the present invention relates to a composition and food having the function of suppressing appetite, comprising at least one ingredient selected from the group consisting of hesperetin, ginsenoside-Rb1, 3-hydroxyflavone, hesperidin, ginsenoside-Rg1, β-D-glucan, rutin, flavanone, naringin, melatonin, quercetin and ascorbic acid, which has an appetite suppressing effect by suppressing the activity of ghrelin, which is an appetite-stimulating hormone.

Description

Appetite suppressant food ingredient composition comprising a specific compound as an active ingredient

The present invention relates to an appetite suppressant food ingredient composition comprising a specific compound as an active ingredient, more specifically hesperetin (hesperetin), ginsenoside-Rb1 (ginsenoside-Rb1), 3-hydroxyflavone (3- hydroxyflavone, hesperidin, ginsenoside-Rg1, beta-D-glucan, β-D-glucan, rutin, flavonone, naringin, melatonin ( It relates to an appetite suppressing composition and at least one functional food for suppressing appetite containing at least one component selected from the group consisting of melatonin, quercetin and ascorbic acid.

Obesity is the highest in the United States (32% of the population), with a body mass index (BMI) of 30 or higher, and Mexico, 30%, the UK, 23%, Greece, Australia, and New Zealand, 21%. have. In Korea, 1.5% to 2 million people, 3.5% of the total population, are obese, but the population of obesity is increasing very rapidly due to westernization and diversification of dietary life.

Obesity has led to adult disease, including diabetes, hypertension, cardiovascular disease, cancer and mental distress, to some of the causes of death, and also affects national productivity, activity and competitiveness. In particular, the obesity of children and adolescents in Korea, which has undergone many changes in their diet and educational environment, is increasing rapidly, and the recovery of treatment after the onset of pediatric diabetes is not easy, causing serious severity.

Obesity-related treatments have been tried in various ways such as drug administration, exercise, diet, psychotherapy, and surgery, but it is difficult to improve by specific methods, and complex treatments and patient will are important. In the case of drug administration, the drug was developed on the basis of lipolysis or digestive enzyme inhibition, but it has side effects.

As a solution to obesity, a method of degrading and accumulating mast cells or inhibiting digestive enzymes has been generally attempted. If food is supplied to the body, digestion or lipolysis has a limited role compared to the rate and amount of ingestion.

Thus, appetite control (appetite control) to fundamentally regulate the intake of food can be an approach to the fundamental solution, the appetite suppression by the food ingredient composition as a first attempt is meaningful as an invention with novelty, originality and progressiveness Have

Currently, reductil has been released as a drug to control obesity due to appetite control, but it is required to access food or natural products with side effects such as loss of appetite, insomnia, depression, and blood pressure. Therefore, there is a need for a composition for appetite suppression that can contribute to suppression of obesity by creating a new value as an appetite suppressing food material while minimizing side effects.

The present invention first developed an appetite suppression method by a food ingredient composition as a means of preventing obesity, and in the method of demonstrating the appetite suppression effect, a test system for suppressing ghrelin that promotes appetite is first discovered in a cell differentiation degree. Therefore, food ingredients were applied and appetite suppression effects were scientifically verified.

Korean Patent Publication No. 2004-0097813 discloses an anti-obesity functional composition having three functions such as appetite suppression, body fat reduction, and bowel activation. Korean Patent Publication No. 2004-0036111 discloses ginseng and polyphenol-based substances or bioflavonoids. Foods for improving lipid metabolism and anti-obesity including a powder or extract of a plant comprising a systemic substance have been disclosed, but differ from the appetite suppressing food ingredient composition of the present invention.

The present invention is derived from the above requirements, the present invention is desired to develop a functional material that can suppress the appetite, but many limitations due to safety problems such as limitations and side effects of body fat decomposition, digestion inhibition method Nowadays, hesperetin, ginsenoside-Rb1, 3-hydroxyflavone, hesperidin, hesperidin and ginsenoside Ginsenoside-Rg1, beta-D-glucan, β-D-glucan, rutin, flavonone, naringin, melatonin, quercetin and ascorbic acid The present invention was completed by developing an appetite suppressing composition containing at least one component selected from the group consisting of acid) as an active ingredient.

In addition, the present invention first developed an appetite suppression method by a food ingredient composition as a solution to obesity suppression, and also in the method of proving appetite suppression effect, by first discovering a test system that suppresses Ghrelin to promote appetite according to the degree of cell differentiation Food ingredients were applied and appetite suppression effects were scientifically verified.

In order to solve the above problems, the present invention is an active ingredient hesperetin (hesperetin), ginsenoside-Rb1 (ginsenoside-Rb1), 3-hydroxyflavone (3-hydroxyflavone), hesperidin (hesperidin), ginsenoside Ginsenoside-Rg1, beta-D-glucan, beta-D-glucan, rutin, flavonone, naringin, melatonin, quercetin and ascorbic acid It provides a composition for suppressing appetite containing at least one component selected from the group consisting of ascorbic acid).

In addition, the present invention, hesperetin (hesperetin), ginsenoside-Rb1 (ginsenoside-Rb1), 3-hydroxyflavone (3-hydroxyflavone), hesperidin (hesperidin), ginsenoside-Rg1 (ginsenoside-Rg1), Beta-D-glucan, rutin, flavonone, flanone, naringin, melatonin, quercetin and ascorbic acid It provides a functional food for suppressing appetite containing at least one ingredient as an active ingredient. In the method of proving appetite suppression effect, a test system that suppresses ghrelin that promotes appetite was first discovered, and food ingredients were applied according to the degree of cell differentiation, and the appetite suppression effect of food ingredients was scientifically verified.

According to the present invention, the appetite suppressant composition of the present invention is effective for suppressing appetite, and because it uses food ingredients, no side effects appear even after taking for a long time, and it is possible to secure safety, very useful in functional food industry for appetite suppression It will be an invention.

In addition, the method to prove the appetite suppression effect was the first to discover the ghrelin test system that promotes appetite, and to provide the first model to scientifically verify the appetite suppression effect by applying food ingredients according to the degree of cell differentiation.

FIG. 1 shows the concentration of ghrelin as a multinucleate differentiation inhibitory activity when 0.1 μg / ml of each food ingredient is added to human umbilical vein endothelial cell (HUVEC) cells.

1: 3-hydroxyflavone, 2: rutin, 3: quercetin, 4: flavonone, 5: naringin, 6: hesperidin, 7 : Catechin, 8: caffeine, 9: theobromine, 10: capsaicin

FIG. 2 shows the concentration of ghrelin as a multinucleate differentiation inhibitory activity when 1 or 10 ㎍ / ml of each food ingredient is added to human umbilical vein endothelial cells (HUVEC) cells. .

1: sibutramine (positive control), 2: ascorbic acid, 3: beta-D-glucan, 4: hesperetin, 5: alpha-lipoic acid (α) -lipoic acid), 6: serotonin, 7: melatonin, 8: alpha-tocopherol, 9: ginsenoside-Rb1, 10: ginsenoside-Rg1 (ginsenoside-Rg1), 11: naringenin

FIG. 3 shows that each food ingredient is treated at 60 ° C., 80 ° C. and 100 ° C. for 5 minutes, and then food ingredients are added to human umbilical vein endothelial cells (HUVEC) cells, respectively, and the amount of ghrelin is measured. .

Figure 4 is treated with each food ingredient at 60 ℃, 80 ℃ and 100 ℃ for 5 minutes, and then added food ingredients to human umbilical vein endothelial cells (HUVEC) cells, respectively, the cell proliferation capacity and the amount of ghrelin (ghrelin) It is measured.

FIG. 5 shows that the food ingredients are added to human umbilical vein endothelial cells (HUVEC) cells after treatment of each food ingredient at

pH

2, 5 and 7 within 5 minutes, respectively, and the amount of ghrelin is measured.

FIG. 6 shows that each food ingredient is treated within 5 minutes at

pH

2, 5, and 7, and then the food ingredient is added to human umbilical vein endothelial cells (HUVEC) cells to measure cell proliferation and ghrelin levels. It is.

Figure 7 shows the weight change and dietary intake of the rats in the normal diet (control), high fat diet (control), high fat diet + 3-hydroxyflavone (3-hydroxyflavone) administration group (A) respectively .

Figure 8 shows the rats in the normal diet group (normal), high fat diet (control), high fat diet + 3-hydroxyflavone (3-hydroxyflavone) administration group (A) and the activity of the rats, respectively.

In order to achieve the object of the present invention, the present invention is an active ingredient hesperetin (hesperetin), ginsenoside-Rb1 (ginsenoside-Rb1), 3-hydroxyflavone (3-hydroxyflavone), hesperidin (hesperidin), gin Ginsenoside-Rg1, beta-D-glucan, β-D-glucan, rutin, flavonone, naringin, melatonin, quercetin and ascorbate It provides a composition for suppressing appetite containing at least one component selected from the group consisting of acid (ascorbic acid).

In the composition of the present invention, the appetite suppression may be an effect of inhibiting the activity of ghrelin (ghrelin), an appetite-stimulating hormone.

The active ingredient included in the composition of the present invention may maintain ghrelin inhibitory activity even after 5 minutes treatment at a temperature of 60 ~ 100 ℃. From this, the ghrelin inhibitory activity is maintained even when the food ingredient is heated, thereby indirectly confirming the possibility of maintaining appetite suppressing activity of the food ingredient during processing.

In addition, the active ingredient included in the composition of the present invention can maintain the ghrelin inhibitory activity even after 5 minutes treatment at pH 2 ~ 10. From this, it was indirectly determined that the appetite suppression effect was maintained overall by suppressing ghrelin activity even when ingesting food components in the body.

Appetite suppressing compositions of the present invention may include suitable carriers, excipients and diluents commonly used in the manufacture of pharmaceutical compositions.

Pharmaceutical dosage forms of the appetite suppressant composition of the present invention may be used in the form of their pharmaceutically acceptable salts, and may be used alone or in combination with other pharmaceutically active compounds, as well as in a suitable collection.

The appetite suppressing composition according to the present invention is formulated in the form of powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols and the like, external preparations, suppositories, and sterile injectable solutions, respectively, according to a conventional method. Can be used. Carriers, excipients and diluents that may be included in the appetite suppressant composition include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, Various compounds or mixtures, including cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, mineral oil and the like. When formulated, diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrating agents, and surfactants are usually used. Solid preparations for oral administration include tablets, pills, powders, granules, capsules and the like, and such solid preparations include at least one excipient such as starch, calcium carbonate and sucrose in the ingredients. ) Or lactose, gelatin and the like are mixed. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Oral liquid preparations include suspensions, solvents, emulsions, and syrups, and may include various excipients, such as wetting agents, sweeteners, fragrances, and preservatives, in addition to commonly used simple diluents such as water and liquid paraffin. . Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, suppositories. As the non-aqueous solvent and suspending agent, propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate and the like can be used. As the base of the suppository, witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerogelatin and the like can be used.

Preferred dosages of the appetite suppressant composition of the present invention vary depending on the condition and weight of the patient, the extent of the disease, the form of the drug, the route of administration and the duration, and may be appropriately selected by those skilled in the art. However, for the desired effect, the appetite suppressing composition of the present invention is preferably administered at 0.0001 to 100 mg / kg, preferably 0.001 to 100 mg / kg per day. Administration may be administered once a day or may be divided several times. The dosage does not limit the scope of the invention in any aspect.

The appetite suppressant composition of the present invention can be administered to various mammals such as mice, mice, livestock, humans. All modes of administration can be expected, for example by oral, rectal or intravenous, intramuscular, subcutaneous, intrauterine dural or intracerebroventricular injection.

The invention also relates to hesperetin, hesperetin, ginsenoside-Rb1, 3-hydroxyflavone, 3-hydroxyflavone, hesperidin, ginsenoside-Rg1, ginsenoside-Rg1, Beta-D-glucan, rutin, flavonone, flanone, naringin, melatonin, quercetin and ascorbic acid It provides a functional food for suppressing appetite containing at least one ingredient as an active ingredient.

When the appetite suppressing composition of the present invention is used as a food additive, the appetite suppressing composition may be added as it is or used with other foods or food ingredients, and may be appropriately used according to a conventional method. The blending amount of the active ingredient can be suitably determined according to the purpose of its use (prevention, health or therapeutic treatment). Generally, in the manufacture of food or beverages the components of the invention are added in an amount of up to 15 parts by weight, preferably up to 10 parts by weight relative to the raw materials. However, in the case of long-term intake for health and hygiene or health control, the amount may be below the above range, and the active ingredient may be used in an amount above the above range because there is no problem in terms of safety. .

There is no particular limitation on the kind of food. Examples of the food to which the substance can be added include dairy products including meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gums, ice cream, various soups, drinks, tea, drinks, Alcoholic beverages and vitamin complexes, and the like and include all foods in a conventional sense.

The functional beverage composition containing the meat suppressing composition of the present invention may contain various flavors, natural carbohydrates, and the like as additional components, as in general beverages. The above-mentioned natural carbohydrates are glucose, monosaccharides such as fructose, disaccharides such as maltose and sucrose, and polysaccharides such as dextrin and cyclodextrin, sugar alcohols such as xylitol, sorbitol and erythritol. As the sweetening agent, natural sweetening agents such as tautin and stevia extract, synthetic sweetening agents such as saccharin and aspartame, and the like can be used. The ratio of the natural carbohydrate is generally about 0.01 to 0.04 g, preferably about 0.02 to 0.03 g per 100 ml of the composition of the present invention.

In addition to the above, the appetite suppressing composition of the present invention includes various nutrients, vitamins, electrolytes, flavoring agents, coloring agents, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloid thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, Alcohols, carbonating agents used in carbonated drinks, and the like. In addition, the appetite suppressing composition of the present invention may contain a flesh for preparing natural fruit juice, fruit juice beverage and vegetable beverage. These components can be used independently or in combination. The proportion of such additives is not critical but is generally selected in the range of 0.01 to 0.1 parts by weight per 100 parts by weight of the composition of the present invention.

Hereinafter, the present invention will be described in more detail with reference to Examples. However, these examples are for illustrative purposes only and the scope of the present invention is not limited to these examples.

1. 시료의 확보1. Securing Sample

(1) Selection of appetite suppression material

The food ingredient for appetite suppression test system is to make it possible to obtain a single ingredient, and it is 3-hydroxyflavone, rutin, quercetin, flavonone, flavonone, Naringin, hesperidin, catechin, capsaicin, caffeine, theobromine, ascorbic acid, beta-D-glucan, β-D-glucan, Hesperetin, lipoic acid, serotonin, serotonin, melatonin, tocopherol, ginsenoside-Rb1, ginsenoside-Rg1, ginsenoside-Rg1, Naringenin and sibutramine (sibutramin, positive control) were obtained.

(2) Preparation of Cell Test Sample Solution

The target food ingredients were dissolved in DMSO, diluted and used for each concentration. The final concentration of DMSO was 0.1% or less to prepare a cell test sample solution.

2. 식욕 촉진 호르몬 그렐린(ghrelin)의 활성 시험2. Test of appetite-stimulating hormone ghrelin

(1) HUVEC cell culture

HUVEC (human umbilical vein endothelial cells) was used by Young Science. 37 ° C using EGM-2 medium (FBS, Hydrocortisone, hFGF, VEGF.R3-IGF-1, Ascorbic acid, hEGF, GA-1000, Heparin) in a 100 mm dish coated with 2% gelatin , And incubated in an incubator maintained at 5% CO ₂ . When the cells were confluent, the cells were passaged with trypsin-EDTA and the medium was exchanged every 2 to 3 days.

(2) ghrelin assay

Samples for ghrelin analysis were separated into supernatant and cell lysate. After completion of the experiment, the recovered culture was centrifuged (3,000 rpm, 20 minutes, 4 ℃) to recover only the supernatant, cell lysate was centrifuged for 10 minutes at 10000 rpm after separating the cells with Trypsin-EDTA. After removing the supernatant and preparing a cell lysate using a solution containing 1% of Triton X-100 in the obtained cells, the content of ghrelin was measured using a HUMAN unacylated ghrelin kit (SPI-Bio). In other words, the method of measuring ghrelin was placed in a well of standard diluent buffer and 100 ul of sample, and 100 ul of anti-unacylated ghrelin-AChE tracer was added. After 3 hours of incubation at room temperature, the culture solution was completely removed and washed 5 times with diluted wash solution. After drying the plate, absorbance was measured at 405 nm after adding 200 ul of Ellman's reagent.

3. 온도와 pH에 따른 식품성분의 세포증식능과 그렐린(ghrelin) 억제 활성3. Cell Proliferation and Ghrelin Inhibitory Activity of Food Ingredients According to Temperature and pH

(1) Changes in Cell Proliferation and Ghrelin Inhibition Activation of Food Ingredients with Temperature

In order to investigate the stability during processing of food ingredients, the inhibitory activity of ghrelin, an appetite-stimulating hormone according to heating temperature, was investigated for food ingredient concentrations that had high inhibitory activity against ghrelin. After a certain amount of food ingredients were treated at 60 ° C., 80 ° C. and 100 ° C. for 5 minutes, and prepared at concentrations having high inhibitory activity against ghrelin, the cell proliferation ability and the amount of ghrelin were measured.

(2) Changes in Cell Proliferation and Ghrelin Inhibition Activation of Food Ingredients According to pH

To indirectly test the body's activity of appetite suppression of food ingredients, the ghrelin inhibitory activity was investigated according to the pH change of food ingredients under acidic, neutral and basic conditions. Each food solution was dipped in each pH solution at a concentration of 10% within 5 minutes, and then lyophilized to prepare a concentration having high inhibitory activity against ghrelin, and then the cell proliferation ability and the amount of ghrelin were measured.

4. 동물실험4. Animal Experiment

(1) Experimental animal breeding

The experimental animals were 4 weeks old C57BL / 6J male mice, and the day and night cycle (12 hours light / 12 hours night) was controlled and the indoor temperature was raised in the animal breeding room of 22 ~ 25 ℃. One week of adaptation mice were fed high fat diets supplemented with 40% bee tallow to normal diet for 8 weeks to induce the high fat diet group. During the experiment, the experimental animals were divided into the normal group and the high-fat diet group, and the dietary intake and body weight were measured periodically.

Table 1

Experimental dietary composition (g / Kg diet)

ingredient	Normal diet ¹⁾	High-fat diet ²⁾
Casein	200	200
DL-Methionine	3	3
Corn starch	150	150
Sucrose	500	345
Cellulose	50	50
Corn oil	50	-
Beer tallow	-	205
Salt mixture	35	35
Vitamin mixture	10	10
Choline bitartrate	2	2
Fat% (Calories)	11.7	40.0

¹⁾ Normal diet: AIN-76A diet # 100000 (Dyets Inc., Bethlehem, PA, USA)

²⁾ High-fat diet: AIN-76 diet # 100496 (Dyets Inc., Bethlehem, PA, USA)

(2) Selection of candidate material for preliminary animal experiment

In the laboratory, 3-hydroxyflavone, a food ingredient expected to have anti-obesity effect, was treated by intraperitoneal administration to high-fat diet mice at a concentration of 10 mg / kg for 3 weeks.

(3) measuring locomotor activity

Use the S-mart program (Pan Lab, Spain), a program that measures all movements of a given place using a computer sensor, for 1 hour in a white matt acrylic box of 40 × 40 × 40 cm in width, length, and height. The behavior of was measured after 3 weeks of food ingredient treatment. The image obtained from the digital camera installed about 2.5m above the box is transferred to the computer and tracked according to the movement of the subject by recognizing the center point of the white subject image using the principle of contrasting the white subject against the black background. It was. Then, the trajectory of the movement of the test animal was quantified to quantify the distance moved.

실시예 1: 식품성분 첨가 시 그렐린(ghrelin)의 농도변화Example 1 Changes in Ghrelin Concentration upon Addition of Food Ingredients

Human umbilical vein endothelial cell (HUVEC) cells contain food ingredients (3-hydroxyflavone, rutin, quercetin, flavonone, naringin, hesperidin, When catechin, capsaicin, caffeine, and theobromine were added at 0.1 ㎍ / ml, the concentration of ghrelin was measured by multinucleate differentiation inhibitory activity compared to the control. (FIG. 1). As a result, the concentration of ghrelin (ghrelin) was 79% compared to the control, and the content of ghrelin was lower than 20%, and quercetin was 90% compared to the control. Showed relatively high ghrelin (ghrelin) content. Compared with the control in all treatments, the content of ghrelin was reduced, and it was confirmed that the effect of suppressing appetite.

In addition, food ingredients (ascorbic acid, beta-D-glucan, hesperetin, lipoic acid, serotonin (HUVEC) cells in human umbilical vein endothelial cells (HUVEC) serotonin, melatonin, tocopherol, ginsenoside-Rb1, ginsenoside-Rg1, naringenin, and sibutramine (sibutramin, positive control) The concentration of ghrelin was measured as multinucleate differentiation inhibitory activity compared to the control when added at 1 or 10 μg / ml, respectively (FIG. 2). In the multinucleate state, the samples were treated by setting the time of rapid increase in the proliferation rate to 30 hours of passage culture. As a result, sibutramine, a positive control, had a content of 75% (25% inhibition) at a concentration of 1 ug / ml, and high ghrelin at 68% (32% inhibition) at 10 ug / ml. Inhibitory activity was ascorbic acid (ascorbic acid) showed a secretion rate of 93% and 94% at concentrations of 1 ug / ml and 10 ug / ml, respectively. In the case of glucan, the concentration of ghrelin decreased as the concentration of sample increased in concentration-dependent manner, showing the lowest content of 85% at the concentration of 10 ug / ml, and 1 ug / for hesperetin. At the concentration of ml, the highest inhibitory activity was shown to be 79%, and low value of 85% even at 10 ug / ml. Melatonin had a low ghrelin content of 87% at 10 ug / ml, and ginsenoside-Rb1 gradually decreased with increasing concentrations to 76% at 10 ug / ml. Ginsenoside-Rg1 (ginsenoside-Rg1) also showed a tendency to decrease the content of ghrelin in a concentration-dependent manner, showing a low content of 84% at 10 ug / ml. Thus, ascorbic acid, beta-D-glucan, β-D-glucan, hesperetin, melatonin, ginsenoside-Rb1 and ginsenoside-Rg1 Compared to the control in the (ginsenoside-Rg1) treatment, the content of ghrelin was decreased, and it was confirmed that the appetite suppression effect was observed.

실시예 2: 온도에 따른 그렐린(ghrelin)의 함량Example 2 Content of Ghrelin with Temperature

3 and 4 show the content of ghrelin according to the heating temperature of the food ingredient. As a result, the cell proliferation ability according to the temperature was found to maintain the overall cell proliferation ability even when the temperature is increased to 60 ~ 100 ℃. In addition, it was found that the content of ghrelin according to the temperature change is maintained stably. Ghrelin (ghrelin) is mostly 80 ~ 90% in the temperature range of 60 ~ 100 ℃ it was judged that the inhibitory effect is maintained about 20 to 10%. From this, even when the food ingredients are heated, cell proliferation and ghrelin inhibitory activity is maintained, thereby indirectly confirming the possibility of maintaining appetite suppressing activity of the food ingredients during processing.

실시예 3: pH에 따른 그렐린(ghrelin)의 함량Example 3 Content of Ghrelin with pH

In order to indirectly determine the body activity of food ingredients, the content of ghrelin was investigated according to the pH change of food ingredients under acidic, neutral, and basic conditions (FIGS. 5 and 6). As a result, the residual amount of ghrelin was similar to that of the temperature treatment because the residual amount of ghrelin was lower than that of the control in all treatments even when

pH

2, 7 and 10 were changed in the food ingredients. From this, it was indirectly determined that the appetite suppression effect was maintained overall by suppressing ghrelin activity even when ingesting food components in the body.

실시예 4: 실험동물의 식이 섭취량과 체중 변화Example 4 Dietary Intake and Weight Change of Experimental Animals

As a result of comparing the weight change according to the normal diet group, the high fat diet group, and the high fat diet + 3-hydroxyflavone administration group, the weight gain was increased by 8-week high fat diet. Significantly increased, and when administered to 3-hydroxyflavone (3-hydroxyflavone), a decrease in dietary intake was shown, resulting in a decrease in weight gain (Fig. 7).

실시예 5: 보행성 활동량(locomotor activity) 측정Example 5 Locomotor Activity Measurement

After 3 weeks of 3-hydroxyflavone administration to the high-fat diet group to determine whether the inhibition of weight gain following 3-hydroxyflavone administration was due to increased energy consumption In addition, the amount of walking activity was measured. After 1 hour of spatial adaptation, there was no significant difference in any group in the measurement of movement for 2 hours. Therefore, it was confirmed that the effect of inhibiting weight gain by administration of 3-hydroxyflavone was due to a decrease in dietary intake (FIG. 8).

Claims

Hesperetin, Ginsenoside-Rb1, 3-hydroxyflavone, Hesperidin, Ginsenoside-Rg1, Ginsenoside-Rg1, Beta- One selected from the group consisting of D-glucan, rutin, flavonone, flanone, naringin, melatonin, quercetin and ascorbic acid Appetite suppression composition containing the above component.
The appetite suppressing composition of claim 1, wherein the appetite suppressant is an effect of inhibiting the activity of ghrelin, which is an appetite-stimulating hormone.
According to claim 2, wherein the appetite suppressing composition, characterized in that the ghrelin inhibitory activity is maintained at a temperature of 60 ~ 100 ℃.
The composition for suppressing appetite according to claim 2, wherein the composition maintains ghrelin inhibitory activity at pH 2 to 10.
Hesperetin, ginsenoside-Rb1, 3-hydroxyflavone, hesperidin, ginsenoside-Rg1, beta-D-glucan (β-D-glucan), rutin, flavonone (flavanone), naringin (naringin), melatonin (melatonin), quercetin (quercetin) and ascorbic acid (ascorbic acid) Functional food for appetite suppression containing as an active ingredient.